For investors in Singapore

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE0009355771

NAV
USD 43.44
As of 20/05/2022

1-Day Change
USD 0.59 (1.38%)
As of 20/05/2022

Morningstar Rating

Overview

Quarterly update

Watch the investment team recap this quarter.

Note: Filmed in May 2022

OBJECTIVE AND INVESTMENT POLICY

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Performance

Cumulative & Annualised Performance (%)
As of 30/04/2022
A2 USD (Net) A2 USD (With Sales Charge)* MSCI World Health Care NR
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
31/03/2000
A2 USD (Net) -6.94 -3.33 -13.27 -12.01 -7.61 9.65 9.45 13.28 6.95
A2 USD (With Sales Charge)* -11.60 -8.17 -17.61 -16.41 -12.23 7.79 8.33 12.69 6.70
MSCI World Health Care NR -4.63 -0.49 -4.58 -7.84 5.59 13.60 11.42 12.70 7.83
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 31/12/2021)
2.38%

Portfolio

Top Holdings (As of 30/04/2022)
% OF FUND
UnitedHealth Group Inc 6.29
AstraZeneca PLC 4.82
AbbVie Inc 3.78
Roche Holding AG 2.87
Eli Lilly & Co 2.74
Thermo Fisher Scientific Inc 2.72
Bristol-Myers Squibb Co 2.66
Abbott Laboratories 2.58
Merck & Co Inc 2.56
Vertex Pharmaceuticals Inc 2.50
Total 33.52
Sector Allocation % OF FUND % OF FUND (As of 30/04/2022)
Regional Allocation % OF FUND % OF FUND (As of April 30, 2022)

Documents